Medi Assist Healthcare Services Limited (NSE:MEDIASSIST) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Shareholders might have noticed that Medi Assist Healthcare Services Limited (NSE:MEDIASSIST) filed its quarterly result this time last week. The early response was not positive, with shares down 2.8% to ₹352 in the past week. Results look mixed - while revenue fell marginally short of analyst estimates at ₹2.4b, statutory earnings were in line with expectations, at ₹12.14 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Taking into account the latest results, the consensus forecast from Medi Assist Healthcare Services' three analysts is for revenues of ₹10.5b in 2027. This reflects a meaningful 9.7% improvement in revenue compared to the last 12 months. Per-share earnings are expected to ascend 19% to ₹14.80. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹10.5b and earnings per share (EPS) of ₹14.17 in 2027. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.
Check out our latest analysis for Medi Assist Healthcare Services
There's been no major changes to the consensus price target of ₹507, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Medi Assist Healthcare Services, with the most bullish analyst valuing it at ₹540 and the most bearish at ₹480 per share. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Medi Assist Healthcare Services' revenue growth will slow down substantially, with revenues to the end of 2027 expected to display 13% growth on an annualised basis. This is compared to a historical growth rate of 18% over the past three years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 18% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Medi Assist Healthcare Services.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Medi Assist Healthcare Services' earnings potential next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at ₹507, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Medi Assist Healthcare Services going out to 2029, and you can see them free on our platform here..
You should always think about risks though. Case in point, we've spotted 1 warning sign for Medi Assist Healthcare Services you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.